Flerie is a prominent brand that specializes in long-term life science investments, focusing specifically on biotech and pharmaceutical ventures on a global scale. With locations in Stockholm and London, Flerie manages an extensive portfolio of 33 investments across Europe, Israel, and the US. Their main objective is to support groundbreaking organizations within the drug development and related services sector, providing them with essential resources and expertise to thrive.

Boasting an impressive asset under management of over $300 million, Flerie's portfolio includes 23 product development companies, seven commercial growth companies, and three funds. They invest in driven entrepreneurs who possess the ambition to make a significant impact on the industry and are supported by academia and science. Flerie primarily invests in private companies but also selectively invests in public companies and investment funds.

Their investment focus centers around the drug development field, encompassing modalities such as cell and gene therapy, vaccines, biologics, and small molecules. Flerie operates with an evergreen structure, allowing for long-term value creation in their portfolio. They invest off their own balance sheet and recycle the investment pool, aiming to stay invested as long as they can contribute and build value.

From early-stage product development to commercial growth, Flerie supports companies at various stages of growth and profitability. With a commitment to making a difference in the life sciences industry, Flerie is recognized for its dedication to investment and fostering success in cutting-edge organizations